- Home
- PYN vs LPCN Comparison
PYN vs LPCN Comparison
Compare PYN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- LPCN
- Stock Information
- Founded
- PYN 2002
- LPCN 1997
- Country
- PYN United States
- LPCN United States
- Employees
- PYN N/A
- LPCN N/A
- Industry
- PYN Investment Managers
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- PYN Finance
- LPCN Health Care
- Exchange
- PYN Nasdaq
- LPCN Nasdaq
- Market Cap
- PYN 34.6M
- LPCN 36.8M
- IPO Year
- PYN N/A
- LPCN N/A
- Fundamental
- Price
- PYN $6.04
- LPCN $4.94
- Analyst Decision
- PYN
- LPCN Strong Buy
- Analyst Count
- PYN 0
- LPCN 1
- Target Price
- PYN N/A
- LPCN $10.00
- AVG Volume (30 Days)
- PYN 19.9K
- LPCN 30.8K
- Earning Date
- PYN 01-01-0001
- LPCN 11-07-2024
- Dividend Yield
- PYN 5.07%
- LPCN N/A
- EPS Growth
- PYN N/A
- LPCN N/A
- EPS
- PYN N/A
- LPCN N/A
- Revenue
- PYN N/A
- LPCN $7,922,926.00
- Revenue This Year
- PYN N/A
- LPCN N/A
- Revenue Next Year
- PYN N/A
- LPCN N/A
- P/E Ratio
- PYN N/A
- LPCN N/A
- Revenue Growth
- PYN N/A
- LPCN N/A
- 52 Week Low
- PYN $4.84
- LPCN $2.38
- 52 Week High
- PYN $6.60
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- PYN 45.93
- LPCN 44.02
- Support Level
- PYN $5.97
- LPCN $4.79
- Resistance Level
- PYN $6.11
- LPCN $5.40
- Average True Range (ATR)
- PYN 0.10
- LPCN 0.54
- MACD
- PYN 0.01
- LPCN -0.12
- Stochastic Oscillator
- PYN 33.43
- LPCN 16.01
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.